Kidney cancer trial pulled before it even started
NCT ID NCT05487859
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study planned to test whether adding acarbose, a drug normally used for diabetes, could improve standard immunotherapy for advanced kidney cancer. The goal was to see if the combination was safe and affected gut bacteria. However, the trial was withdrawn before enrolling any participants, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Acarbose (a diabetes drug that may affect the immune system)
- What this could lead to
- If it had worked, this could have pointed toward a new way to boost standard immunotherapy for advanced kidney cancer.
- What could go wrong
- The trial was withdrawn before any patients enrolled, so we have no data on safety or effectiveness. Acarbose is not a standard cancer treatment, and its benefits in this setting are entirely unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Old drug, new hope: mercaptopurine tested against rare cancer syndrome
- Could an ALS drug clear the fog of chemo brain?
- Ancient Mind-Body practice tested as fatigue fighter for men after cancer
- Can a website help cancer survivors live healthier? large study tests online lifestyle coaching